ArticleBMC cancer2025
Trends in the disease burden of early-onset cancers in China from 1990 to 2021: a systematic analysis of the 2021 Global Burden of Disease study.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Microplastics in early-onset carcinogenesis.Carcinogenesis · 2026Review
- Temporal clustering of neuroblastic tumours in children and young adults from Scotland.Environmental health : a global access science source · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
backgroundIn recent years, the incidence of early-onset cancers among individuals under 50 years of age has been on the rise. We aimed to analyze the disease burden and temporal trends of early-onset cancers in China, providing a basis for policymakers to develop appropriate strategies.
methodsWe utilized data from the 2021 Global Burden of Disease (GBD) study to describe the changes in early-onset cancers in China from 1990 to 2021, including incidence, mortality and disability-adjusted life years (DALYs). The age-standardized average annual percentage change (AAPC) was estimated using the Joinpoint regression program.
resultsFrom 1990 to 2021, the incidence rate of all early-onset cancers in China increased by 150.72 per 100,000, while the mortality and DALY rates decreased by 4.30 per 100,000 and 279.34 per 100,000, respectively. In 2021, early-onset breast cancer had the highest incidence rate (17.14 per 100,000), and trachea/bronchus/lung cancer had the highest mortality rate (6.15 per 100,000) and DALY rate (292.48 per 100,000). The standardized DALY rate of all early-onset cancers decreased (AAPC = -1.49%, 95% CI: -1.51% to -1.46%), while multiple myeloma, neuroblastoma and other peripheral nervous cell tumors, malignant neoplasm of bone and articular cartilage, kidney cancer, and mesothelioma showed significant increases with AAPC of 4.14% (4.01-4.28%), 3.83% (3.77-3.88%), 1.20% (1.16-1.25%), 0.65% (0.58-0.73%), and 0.33% (0.29-0.37%), respectively. Tobacco consumption (23.01%) was the primary contributor to the disease burden of early-onset cancers in males, whereas unsafe sexual behavior (10.53%) was the primary contributor in females.
conclusionThe mortality and DALY rate of early-onset cancers in China decreased, while the incidence rate increased. Trachea/bronchus/lung cancer is one of the most severe early-onset cancers, and effective measures need to be taken against the main risk factors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.